Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionSubcutaneous RNAi therapeutic against angiotensinogen (AGT)
Molecular Target Angiotensinogen (AGT)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPreclinical
Standard Indication Genitourinary (unspecified)
Indication DetailsTreat preeclampsia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today